Sequelae in adults at 12 months after mild‐to‐moderate coronavirus disease 2019 (COVID‐19)

Boscolo‐Rizzo, Paolo; Guida, Francesco; Polesel, Jerry; Marcuzzo, Alberto Vito; Capriotti, Vincenzo; D’Alessandro, Andrea; Zanelli, Elisa; Marzolino, Riccardo; Lazzarin, Chiara; Antonucci, Paolo; Sacchet, Erica; Tofanelli, Margherita; Borsetto, Daniele; Gardenal, Nicoletta; Pengo, Martino; Tirelli, Giancarlo

doi:10.1002/alr.22832

Cited by 96 publications

(105 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both presenting patient characteristics and clinical management have evolved since. The generalizability of our results may be limited by the potential patient population selection bias, lack of standardized validated questionnaires for reporting the prevalence of COVID-19 symptoms at the international level and the self-reporting of symptoms based on a remote interview (19) as well as the study's single-center, not-blinded, and not-randomized design.…”

Section: Strenghts and Limitationsmentioning

confidence: 99%

“…Coronavirus disease 2019 (COVID- 19) is a severe acute respiratory infection caused by the emergent coronavirus, SARS-CoV-2. Though most infected individuals are asymptomatic, SARS-CoV-2 infection may cause symptoms ranging from mild to severe acute respiratory distress, with a substantial fraction of patients requiring hospitalization (estimated to be around 10%) and many patients experiencing prolonged symptoms and complications for weeks or months after the initial period of acute illness [1][2][3][4][5][6] .…”

Section: Introductionmentioning

confidence: 99%

“…Since COVID-19 has spread globally, and long COVID became a burgeoning health concern 10 , a growing number of studies has been focused on "long-term effects of COVID-19" [11][12][13][14][15][16][17][18] . However, to date only a few studies [19][20][21][22][23][24] really addressed long term (up to 12 months) sequelae for hospitalized patient populations, as well as temporal trends and longstanding health consequences for "long-haulers" with a whole patient pathway perspective in different populations, timepoints, settings and countries. The full range of long-term health consequences of COVID-19 in patients who were discharged from hospital is largely unclear 25 .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

“Long COVID” follow-up pathway: results of longitudinal cohort study to investigate 6- and 12-month outcomes after hospitalization for SARS-CoV-2 infection

Rigoni¹,

Torri²,

Nollo³

et al. 2021

Preprint

View full text Add to dashboard Cite

Long-term sequelae of symptomatic infection caused by SARS-CoV-2 are largely undiscovered. We performed a prospective cohort study on consecutively hospitalized Sars-CoV-2 patients (March-May 2020) for evaluating COVID-19 outcomes at 6 and 12 months. After hospital discharge, patients were addressed to two follow-up pathways based on respiratory support needed during hospitalization. Outcomes were assessed by telephone consultation or ambulatory visit. Among 471 patients, 81.6% received no respiratory support during hospitalization; 8.2% received non-invasive ventilation; 0.2% required invasive mechanical ventilation (IMV). 64 patients died during hospitalization, therefore 407 were enrolled for follow-up. At 6 months, among 355patients, the 27.0% had any symptoms, 19.4% dyspnea, 5.4% neurological symptoms. Fifty-two out of 104 had major damages in interstitial Computed Tomography images. IMV patients had higher probability to suffer of neurological symptoms (OR=4.12, p=0.01). At 12 months, among 344, the 24.4% suffered on any symptoms, 14.0% dyspnea, 10.0% neurological symptoms. Severe interstitial lesions were present in 37 out of 47 investigated patients. IMV patients in respect to no respiratory support, had higher probability of experiencing symptoms (OR=3.51, p<0.01), dyspnea (OR=3.08, p<0.01 ), neurological symptoms (OR= 11.50, p<0.01). COVID-19 patients showed prolonged sequelae up to 12 months, highlighting the need of follow-up pathways for post-COVID-19 syndrome.

show abstract

Section: Strenghts and Limitationsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

“Long COVID” follow-up pathway: results of longitudinal cohort study to investigate 6- and 12-month outcomes after hospitalization for SARS-CoV-2 infection

Rigoni¹,

Torri²,

Nollo³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…At 3-7 months follow-ups of COVID-19 patients, ageusia, dysgeusia and hypogeusia persisted in 1.6-7.3% of Chinese and Japanese patients [40,43,52], but in 5.0-42% of French, Italian, American, Norwegian, Israeli, German, and British patients [41,42,[44][45][46][47][48][49][50][51][53][54][55]. For longer follow-up time (to 12 months), gustatory (and olfactory) dysfunction was observed in 25.8% of Israeli patients [57], 12.7% of Italian patients [58] and 22.0% of Italian patients [59]. Persistent gustatory dysfunction is likely to be less prevalent in Asian patients compared with patients in other countries, suggesting that ethnicity may be a risk factor to prolong gustatory dysfunction in COVID-19 survivors.…”

Section: Ethnicitymentioning

confidence: 99%

Persistent Gustatory Dysfunction in COVID-19 Survivors: A Narrative Literature Review

Tsuchiya

2021

JAMMR

View full text Add to dashboard Cite

Patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit a diverse spectrum of clinical manifestations, some of which last for a long time, making a great impact on the healthcare of patients who recovered from coronavirus disease 2019 (COVID-19). Although taste disorders have been well-recognized to be closely associated with COVID-19, understanding of gustatory sequelae is relatively poor compared with oral symptoms in the early phase of COVID-19. The aim of this study was to characterize gustatory dysfunction in COVID-19 survivors by a narrative literature review of follow-up studies and to speculate the pathogenic mechanisms underlying such a persistent symptom. Scientific articles were retrieved by searching PubMed, LitCovid, ProQuest, medRxiv and bioRxiv from 1 April 2020 with a cut-off date of 10 September 2021. The follow-up time periods of the relevant 49 studies ranged from 4 weeks to 12 months. Results of the literature search indicated that ageusia, hypogeusia and/or dysgeusia persist in up to 45.0% of COVID-19 survivors and that the prevalence of these taste impairments varies depending on ethnicity, age, gender and disease severity of patients. Gustatory dysfunction can be detected at high frequency even one year after symptom onset. Persistence of gustatory dysfunction is pathogenically related to expression of SARS-CoV-2 cellular entry-relevant receptors in taste cells and neural cells, decreased saliva secretion, zinc deficiency, disturbed nervous system and inflammation associated with persistent SARS-CoV-2 infection. Given the long-term persistence of gustatory dysfunction in COVID-19 survivors, their discharge from hospital is not the end of disease. Careful attention should be continuously paid to taste perception of post-COVID-19 patients to recover the health-relating quality of life, which is required for health providers, especially dental professionals who not only may experience COVID-19 survivors but also can easily become aware of their taste abnormalities.

show abstract

“…Thus, a dysregulated host immune response was identified that causes a life-threatening cytokine storm and subsequent immune paralysis, leading to multiple organ failure and death. And even though mild-tomoderate COVID-19 does not seem to be associated with a fulminant immune activation, more and more data point to long lasting infection related sequelae including persisting nausea, fatigue and loss of smell and taste in up to 30% of patients who recovered from COVID-19 (10)(11)(12). Hence, even non-severe COVID-19 may pose a considerable hazard for global health and economy.…”

Section: Introductionmentioning

confidence: 99%

Distinguishing Incubation and Acute Disease Stages of Mild-to-Moderate COVID-19

Müller

Volzke

Subin

et al. 2021

Preprint

View full text Add to dashboard Cite

Objective: While numerous studies have already compared the immune responses against SARS-CoV-2 in severely and mild-to-moderately ill COVID-19 patients, longitudinal trajectories are still scarce. We therefore set out to analyze serial blood samples from mild-to-moderately ill patients in order to define the immune landscapes for differently progressed disease stages. Methods: Twenty-two COVID-19 patients were subjected to consecutive venipuncture within seven days after diagnosis or admittance to hospital. Flow cytometry was performed to analyze peripheral blood immune cell compositions and their activation as were plasma levels of cytokines and SARS-CoV-2 specific immunoglobulins. Healthy donors served as controls. Results: Integrating the kinetics of plasmablasts and SARS-CoV-2 specific antibodies allowed for the definition of three disease stages of early COVID-19. The incubation phase was characterized by a sharp increase in pro-inflammatory monocytes and terminally differentiated cytotoxic T cells. The latter correlated significantly with elevated concentrations of IP-10. Early acute infection featured a peak in PD-1+ cytotoxic T cells, plasmablasts and increasing titers of virus specific antibodies. During late acute infection, immature neutrophils were enriched whereas all other parameters returned to baseline. Conclusion: Our findings will help to define landmarks that are indispensable for the refinement of new anti-viral and anti-inflammatory therapeutics, and may also inform clinicians to optimize treatment and prevent fatal outcome.

show abstract

Sequelae in adults at 12 months after mild‐to‐moderate coronavirus disease 2019 (COVID‐19)

Cited by 96 publications

References 10 publications

“Long COVID” follow-up pathway: results of longitudinal cohort study to investigate 6- and 12-month outcomes after hospitalization for SARS-CoV-2 infection

“Long COVID” follow-up pathway: results of longitudinal cohort study to investigate 6- and 12-month outcomes after hospitalization for SARS-CoV-2 infection

Persistent Gustatory Dysfunction in COVID-19 Survivors: A Narrative Literature Review

Distinguishing Incubation and Acute Disease Stages of Mild-to-Moderate COVID-19

Contact Info

Product

Resources

About